8-vinylestra-1,3,5(10)-triene-3,17β-diol | 367929-02-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 8-vinylestra-1,3,5(10)-triene-3,17β-diol
• 英文别名: 8beta-VE2；8-beta-vinyl-estra-1,3,5(10)-trien-3,17-beta-diol；8β-vinyl-estra-1,3,5(10)-trien-3,17β-diol；8β-vinyl-estra-1,3,5(10)-triene-3,17β-diol；D5KU4Jgs7Y；(8S,9S,13S,14S,17S)-8-ethenyl-13-methyl-7,9,11,12,14,15,16,17-octahydro-6H-cyclopenta[a]phenanthrene-3,17-diol
• CAS: 367929-02-0
• 化学式: C₂₀H₂₆O₂
• 分子量: 298.425
• InChiKey: NMCRWZRLOOYKTG-SWBPCFCJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  22
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  8-vinylestra-1,3,5(10)-triene-3,17β-diol 、 叔丁基二甲基氯硅烷 在 咪唑 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 3,17β-bis-(tert-butyldimethylsilyloxy)-8β-vinyl-estra-1,3,5(10)-triene
  参考文献：
  名称：

  Prodrugs of ERbeta-selective substances, process for their production, and pharmaceutical compositions that contain these compounds

  摘要：

  这项发明提供了8β-取代雌三烯类的前药，其一般式为（I），其中基团Z与类固醇相结合，以及它们的生产过程、含有这些化合物的制药组合物以及它们的用途。根据本发明，一般式I的化合物不结合雌激素受体α和/或β，而是结合碳酸酐酶并抑制这些酶。

  公开号：

  US20070197488A1

文献信息

• 8beta-Vinyl-11beta-(omega-substituted)alkyl-estra-1,3,5(10)-trienes
  申请人：Braeuer Nico

  公开号：US20050065135A1

  公开（公告）日：2005-03-24

  This invention relates to 8β-vinyl-11β-(ω-substituted)alkyl-estra-1,3,5(10)-trienes of general formula I with ERβ-antagonistic activity, process for their production, their intermediate products, pharmaceutical preparations that contain the compounds according to the invention, as well as their use for the production of pharmaceutical agents. The new compounds can be used for contraception in men and women without influencing other estrogen-sensitive organs such as the uterus or the liver. They are also suitable for treating benign or malignant proliferative diseases of the ovary, such as ovarian cancer and granulosa cell tumors.

  这项发明涉及一般式I的8β-乙烯基-11β-(ω-取代)烷基-雌甾-1,3,5(10)-三烯具有ERβ拮抗活性，其生产方法，其中间体，含有根据本发明的化合物的制药制剂，以及它们用于制备药物制剂的用途。这些新化合物可用于男性和女性的避孕，而不影响其他对雌激素敏感的器官，如子宫或肝脏。它们还适用于治疗卵巢的良性或恶性增生性疾病，如卵巢癌和颗粒细胞瘤。
• 8 Beta-hydrocarbyl-substituted estratrienes for use as selective estrogens
  申请人：——

  公开号：US20030176405A1

  公开（公告）日：2003-09-18

  This invention describes the new 8&bgr;-substituted estratrienes of general formula I in which R 2 , R 3 , R 6 , R 6′ , R 7 , R 7′ , R 9 , R 11 , R 11′ , R 12 , R 14 , R 15 , R 15′ , R 16 , R 16′ , R 17 and R 17′ have the meanings that are indicated in the description, and R 8 means a straight-chain or branched-chain, optionally partially or completely halogenated alkyl or alkenyl radical with up to 5 carbon atoms, an ethinyl- or prop-1-inyl radical, as pharmaceutical active ingredients that have in vitro a higher affinity to estrogen receptor preparations of rat prostates than to estrogen receptor preparations of rat uteri and in vivo preferably a preferential action on bone rather than the uterus and/or a pronounced action with respect to stimulation of the expression of 5HT2a-receptors and 5HT2a-transporters, their production, their therapeutic use and pharmaceutical dispensing forms that contain the new compounds. The invention also describes the use of these compounds for treatment of estrogen-deficiency-induced diseases and conditions as well as the use of an 8&bgr;-substituted estratriene structural part in the total structures of compounds that have a dissociation in favor of their estrogenic action on bones rather than the uterus.

  本发明描述了新的8&bgr;-取代的环雌三烯通式I，其中R2、R3、R6、R6'、R7、R7'、R9、R11、R11'、R12、R14、R15、R15'、R16、R16'、R17和R17'的含义如说明书所示，而R8表示直链或支链，可选部分或完全卤代的含有最多5个碳原子的烷基或烯基基团，一个乙炔基或丙-1-炔基，作为药物活性成分，具有比大鼠子宫雌激素受体制备更高的亲和力，而且在体内更倾向于对骨骼而不是子宫产生优先作用和/或对5HT2a受体和5HT2a转运体的表达刺激作用显著，本发明还描述了这些化合物的生产、治疗用途和含有新化合物的药物配制形式。本发明还描述了这些化合物用于治疗雌激素缺乏引起的疾病和病症，以及在化合物的总结构中使用8&bgr;-取代的环雌三烯结构部分，以使其更倾向于对骨骼而不是子宫产生雌激素作用的解离。
• 8Beta-Hydrocarbyl-Substituted Estratrienes As Selectively Active Estrogens
  申请人：Peters Olaf

  公开号：US20080182829A1

  公开（公告）日：2008-07-31

  This invention describes the new 8β-substituted estratrienes of general formula I in which R 2 , R 3 , R 6 , R 6′ , R 7 , R 7′ , R 9 , R 11 , R 11′ , R 12 , R 14 , R 15 , R 15′ , R 16 , R 16′ , R 17 , R 17′ have the meanings that are indicated in the description, and R 8 means a straight-chain or branched-chain, optionally partially or completely halogenated alkyl or alkenyl radical with up to 5 carbon atoms, an ethinyl- or prop-1-inyl radical, as pharmaceutical active ingredients that have in vitro a higher affinity to estrogen receptor preparations of rat prostates than to estrogen receptor preparations of rat uteri and in vivo preferably a preferential action on bone rather than the uterus and/or a pronounced action with respect to stimulation of the expression of 5HT2a-receptors and 5HT2a-transporters, their production, their therapeutic use and pharmaceutical dispensing forms that contain the new compounds. The invention also describes the use of these compounds for treatment of estrogen-deficiency-induced diseases and conditions as well as the use of an 8β-substituted estratriene structural part in the total structures of compounds that have a dissociation in favor of their estrogenic action on bones rather than the uterus.

  本发明描述了一种新的8β-取代的雌三烯酮通式I，其中R2、R3、R6、R6′、R7、R7′、R9、R11、R11′、R12、R14、R15、R15′、R16、R16′、R17、R17′具有说明书中所指示的含义，而R8表示直链或支链，可选部分或完全卤代烷基或烯基基团，碳数不超过5个，以太炔基或丙烯基基团，作为具有体外比大鼠前列腺雌激素受体制备亲和力高于大鼠子宫雌激素受体制备的药物活性成分，且在体内优先作用于骨而不是子宫和/或对5HT2a受体和5HT2a转运体的表达刺激具有显著作用，以及它们的生产、治疗用途和包含新化合物的制剂。本发明还描述了这些化合物在治疗雌激素缺乏引起的疾病和病情方面的用途，以及在化合物的总结构中使用8β-取代的雌三烯酮结构部分，以促进它们对骨而不是子宫的雌激素作用的解离。
• DRUG DELIVERY SYSTEM WITH STABILISING EFFECT
  申请人：Funke Adrian

  公开号：US20110052699A1

  公开（公告）日：2011-03-03

  A drug delivery system also intended as unit dosage form comprising a thin water-soluble film matrix, wherein said film matrix comprises a) a polyvinyl alcohol-polyethylene glycol graft copolymer (PVA-PEG graft co-polymer) as a water-soluble matrix polymer; an active ingredient being a steroid in which the positions 6 and 7 of the steroidal skeleton are both a —CH 2 — residue; and said film matrix has a thickness of less than 300 μm.

  一种药物传递系统，也称为单剂量形式，包括一种薄的水溶性膜基质，其中所述的膜基质包括：a）一种聚乙烯醇-聚乙二醇嫁接共聚物（PVA-PEG嫁接共聚物）作为水溶性基质聚合物；b）一种活性成分，其中类固醇的骨架的位置6和7都是—CH2—残基；以及c）所述膜基质的厚度小于300微米。
• Menstrual cycle control and improvement of conception rates in females
  申请人：SCHERING AKTIENGESELLSCHAFT

  公开号：EP1550447A1

  公开（公告）日：2005-07-06

  The present invention relates to methods of increasing likelihood of conception, treatment of low fecundity and/or providing menstrual cycle control without suppressing ovulation in a female comprising administering an effective dose of at least one estrogen and at least one progestin within a treatment period of at least 21 days to 35 days or multiple periods thereof. Furthermore, the invention relates to the combination of at least one estrogen and at least one progestin for the preparation of a medicament to be used in the abovementioned indications. A pharmaceutical kit, according to the invention, comprises 21 to 35 dosage units or a multiple of 21 to 35 dosage units, wherein a first section comprises at most 21 dosage units of at least one estrogen; and a second section comprises from 2 to 34 dosage units of at least one estrogen and from 2 to 34 dosage units of at least one progestin or comprises from 2 to 34 dosage units of at least one estrogen and at least one progestin provided that in each dosage unit containing a progestin or a progestin and an estrogen the progestin is in a non-ovulation inhibiting amount; and ; and optionally a third section comprises at most 10 dosages of a pharmaceutically acceptable placebo or a blank.

  本发明涉及在不抑制女性排卵的情况下增加受孕可能性、治疗低生育力和/或提供月经周期控制的方法，包括在至少21天至35天或其多个治疗期内施用有效剂量的至少一种雌激素和至少一种孕激素。此外，本发明还涉及至少一种雌激素和至少一种孕激素的组合，以制备用于上述适应症的药物。 根据本发明，一种药剂包包括 21 至 35 个剂量单位或 21 至 35 个剂量单位的倍数，其中 第一部分包括最多 21 个剂量单位的至少一种雌激素；以及 第二部分包括 2 至 34 个剂量单位的至少一种雌激素和 2 至 34 个剂量单位的至少一种孕激素，或包括 2 至 34 个剂量单位的至少一种雌激素和至少一种孕激素，条件是在每个含有孕激素或孕激素和雌激素的剂量单位中，孕激素的量为非排卵抑制量；以及 和 第三部分可选择包括至多 10 个剂量的药学上可接受的安慰剂或空白。